Why Intensity Therapeutics Inc (INTS) Stock Is Rising
As of 2026-08-25, Intensity Therapeutics Inc (INTS) has a next-year EPS growth estimate of 35.16%. Featured in our EPS revision report on 2026-08-20.
Why INTS Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Intensity Therapeutics Inc's next-year EPS growth estimate from 30.36% to 35.16% on 2026-08-18.
- ·Current-Year Growth: Projected at 59.46%, supporting the forward estimate revision.
News Context
INTS’s rise is primarily tied to the August 18, 2026 analyst upgrade to next-year EPS growth estimates, from 30.36% to 35.16%. No specific headline catalyst—such as an earnings beat, contract win, or guidance raise—has been reported to explain the revision. Without clear news, the estimate upgrade appears to be the structural driver behind the stock’s move, though it is unclear if momentum has continued beyond
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 35.16%
- EPS growth this year
- 59.46%
- EPS next quarter (est)
- -$0.99
- Last price
- $4.89
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 35.16% | 59.46% | -$0.99 | $4.89 |
| 2026-08-24 | 35.16% | 59.46% | -$0.99 | $4.75 |
| 2026-08-23 | 35.16% | 59.46% | -$0.99 | $4.86 |
| 2026-08-21 | 35.16% | 59.46% | -$0.99 | $4.86 |
| 2026-08-20 | 35.16% | 59.46% | -$0.99 | $4.88 |
| 2026-08-19 | 35.16% | 59.46% | -$0.99 | $4.20 |
| 2026-08-18 | 35.16% | 59.46% | -$0.99 | $4.21 |
| 2026-08-17 | 30.36% | 54.82% | -$0.95 | $4.15 |
| 2026-08-16 | 30.36% | 54.82% | -$0.95 | $3.96 |
| 2026-08-14 | 30.36% | 54.82% | -$0.95 | $3.96 |
| 2026-03-27 | 41.24% | N/A | N/A | $6.03 |
| 2026-03-26 | 41.24% | N/A | N/A | $6.11 |
| 2026-03-26 | 41.24% | N/A | N/A | $6.11 |
| 2026-03-26 | 41.24% | N/A | N/A | $6.11 |
| 2026-03-25 | 41.24% | N/A | N/A | $6.38 |
| 2026-03-25 | 41.24% | N/A | N/A | $6.38 |
| 2026-03-25 | 41.24% | N/A | N/A | $6.38 |
| 2026-03-24 | 41.24% | N/A | N/A | $5.92 |
| 2026-03-24 | 41.24% | N/A | N/A | $5.92 |
| 2026-03-24 | 41.24% | N/A | N/A | $5.92 |
| 2026-03-23 | 41.24% | N/A | N/A | $6.22 |
| 2026-03-20 | 41.24% | N/A | N/A | $5.98 |
| 2026-03-19 | 41.24% | N/A | N/A | $6.33 |
| 2026-03-18 | 41.24% | N/A | N/A | $6.48 |
| 2026-03-17 | 41.24% | N/A | N/A | $6.49 |
Reports Featuring INTS
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Intensity Therapeutics Inc (INTS) stock go up recently?▾
Intensity Therapeutics Inc (INTS) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 30.36% to 35.16% on 2026-08-18. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Intensity Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Intensity Therapeutics Inc (INTS) has a next-year EPS growth estimate of 35.16%, based on analyst consensus.
When was the latest EPS estimate revision for INTS?▾
The most recent revision occurred on 2026-08-18, when analysts adjusted the next-year EPS growth estimate from 30.36% to 35.16%.
What sector and industry does Intensity Therapeutics Inc belong to?▾
Intensity Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. INTS appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Intensity Therapeutics Inc (INTS) appears here because it was detected by our daily top-EPS-revision-performer screen.